Cue Biopharma is trading 5.6% lower at $29.16 in pre-market on September 23, 2026, with no new company-specific announcement or reliable late-breaking catalyst identified. - The decline follows extreme volatility after September 20 Phase 2 CUE-221 results: shares fell 23.70% on September 21, then rebounded 9.30% on September 22. - The broader biotech sector is rising, so sector strength does not explain the decline.